Avid Bioservices Inc (CDMO)

[Protector]

Possibly because they don't want to give 80% away.

Furthermore, more importantly, Cotara isn't just for brain cancer.

It is for all solid cancers. Clinical trials may need to be ran. No idea what impact that has.

Last but not least this form of solid cancer (brain) is a niche. Few patients (relatively) and not all BP's are interested in this (in niches in general).

So a negotiating/targeting problem may be to find a partner for brain and making no commitments about the rest of the Cotara platform.

I also think that the Bavi discrepancy case has set different priorities! And maybe they have a partner and are negotiating, I don't know.

There is of course MUCH MORE leverage if they can enroll 20 patients in a Cotara PIII and with excellent intermediate results sit with a partner. Not sure if they'll be willing to go it alone no matter what is sometimes posted here. I hope not. PPHM must do research, develop Cotara and Bavi, run clinical trials and let others do the field commerce under license.